Clinical Trials Search Tool

New Search / Reset Search

A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease

Disease/Condition: Early Alzheimer’s Disease

Location: Portland

Ages: 55-90

Enrollment Opens: 01-01-2024

Enrollment Closes: TBD

Description:

A once daily oral interventional clinical trial lasting 52 weeks.

Study ID: AR1001-ADP3-US01

To Enroll: Call 503-207-2066

Posted by: Center for Cognitive Health | https://www.centerforcognitivehealth.com/